// App-Quantinova.ai

: Niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Second interim analysis (IA2) of MAGNITUDE.

Researchers

Presenter

  • Eleni Efstathiou

Principal Investigators

  • Shahneen Sandhu

  • Gerhardt Attard

  • Marniza Saad

  • David Olmos

  • Elena Castro

  • Guilhem Roubaud

  • Andrea Juliana Gomes

  • Eric Jay Small

  • Dana E. Rathkopf

  • Howard Gurney

  • Wonho Jung

  • Gary Mason

  • Peter St. John Francis

  • George C. Wang

  • Daphne Wu

  • Brooke Diorio

  • Angela Mennicke Lopez- Gitlitz

  • Kim N. Chi

Medical Centers

  • Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA

  • MQ Health Macquarie University Health Sciences Centre, Macquarie Park, Australia

  • Janssen Research and Development, Titusville, NJ

  • Hospital Universitario 12 de Octubre. Instituto de Investigación Sanitaria Hospital 12 de Octubre, Madrid, Spain

  • University of California, San Francisco, San Francisco, CA

  • BC Cancer - Vancouver Centre, Vancouver, BC, Canada

  • Liga Norte Riograndense Contra o Cncer, Natal, Brazil

  • Department of Clinical Oncology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia

  • Hospital Virgen de la Victoria, Malaga, Spain

  • Institut Bergonie, Bordeaux, France

  • Keimyung University Dongsan Hospital, Daegu, South Korea

  • Houston Methodist Cancer Center, Houston, TX

  • The Institute of Cancer Research, King's College, London, United Kingdom

  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

  • Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia

Locations

  • Malaysia

  • Republic of South Korea

  • France

  • Canada

  • Spain

  • Australia

  • United Kingdom

  • Brazil

  • United States

Companies

  • JB Medical Ltd.

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • BRCA mutation

  • Hormone receptor

  • Thrombospondin-1

Drug/Treatment

  • CB-7598

  • Prednisone

  • Niraparib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Cohort

Phase

  • III

Study Id's

  • NCT03748641

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved